Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inozyme Pharma

4.00
0.0000
Volume:- -
Turnover:- -
Market Cap:259.66M
PE:-2.38
High:4.00
Open:4.00
Low:4.00
Close:4.00
Loading ...

Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition

TIPRANKS
·
01 Jul

Inozyme Pharma Inc. Announces Delisting from Nasdaq and Deregistration of Shares Following Merger

Reuters
·
01 Jul

BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma

MT Newswires Live
·
01 Jul

Biomarin Announces Completion of Acquisition of Inozyme

THOMSON REUTERS
·
01 Jul

Trading in risky penny stocks is booming. Why it could be a sign of trouble ahead for the market.

Dow Jones
·
01 Jul

Inozyme Pharma Inc - Postpones 2025 Annual Meeting of Stockholders

THOMSON REUTERS
·
21 Jun

Press Release: Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Dow Jones
·
21 Jun

Inozyme Pharma Reports Increased Loss Amid Strategic Focus

TIPRANKS
·
10 Jun

Inozyme Pharma Announces Transaction Bonuses for Key Executives Following Merger Agreement

Reuters
·
02 Jun

Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform

MT Newswires Live
·
19 May

Strategic Acquisition of INZY Boosts BioMarin’s Growth Potential and Pipeline Expansion

TIPRANKS
·
19 May

U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma

Reuters
·
19 May

Inozyme Pharma Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
19 May

Inozyme Pharma Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $4 From $23

THOMSON REUTERS
·
19 May

Inozyme Pharma Inc : Raymond James Cuts to Market Perform From Outperform

THOMSON REUTERS
·
19 May

Inozyme Pharma Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
17 May

Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment

TIPRANKS
·
17 May

Inozyme downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
17 May

Sector Update: Health Care Stocks Rise Friday Afternoon

MT Newswires Live
·
17 May

Inozyme Pharma Cut to Hold From Buy by Needham

Dow Jones
·
17 May